Opinion|Videos|February 11, 2025
Patient Perspectives on Managing Side Effects from Amivantamab
Panelists discuss the side effects Melinda has experienced with her current treatment and the strategies she has found most helpful in managing them, while Julia outlines her typical monitoring and follow-up procedures for patients receiving amivantamab, including the frequency of follow-up visits, labs, imaging, and the symptoms or labs that are most concerning during follow-up.
Advertisement
Video content above is prompted by the following:
- Dr. Spira asks Melinda: What side effects have you experienced with your current treatment?
- What strategies have you found to be most helpful in managing these side effects?
- Dr. Spira asks Julia: Briefly outline your typical monitoring and follow-up procedures for patients receiving amivantamab at your institution.
- How often do you see your patients for follow up?
- What labs and imaging are typically ordered and at what frequency?
- During follow up, what symptoms or labs are most concerning to you?
Advertisement
Related to this article
Ralph V. Boccia, MD, FACP, discusses CAR T and bispecific sequencing, fixed-duration therapy, MRD, and bispecifics in AL amyloidosis.
“Those of us who work with NK cells have no doubt that they are incredibly powerful at killing cancer cells,” said Veronika Bachanova, MD, PhD.
Tyler Wilhite, MD, discusses expanding a radiation oncology program to also utilize low-dose radiation therapy for benign diseases.
Allen Khodab, MD discussed how patients with larger prostates had reduced IPSS scores that normalized to the same level as those with normal-sized glands.
Jeffrey V. Matous, MD, explains why ramantamig’s MRD negativity rates are clinically significant in relapsed/refractory myeloma.
In the phase 2 RALLY-MF study, selcodebart produced a 55% major response rate among evaluable non–transfusion-dependent patients with myelofibrosis.
Experts in multiple myeloma discussed long-term MAIA and CEPHEUS trial data and their implications for daratumumab-based regimens in newly diagnosed disease.
Adjuvant radiotherapy significantly reduced meningioma recurrence or death vs observation in grade 2 atypical meningioma after complete surgical resection.
Advertisement
Advertisement
Trending on CancerNetwork
1
Sequencing Bispecifics and CAR T-Cell Therapy in Myeloma and AL Amyloidosis
2
Clinical Applications and the Future of Remote Endovascular Procedures
3
Building a Low-Dose Radiation Therapy Program for Benign Disease
4
FDA Approves Atezolizumab/Chemo for Stage III dMMR Colon Cancer
5